Search research articles
Contact Us
Filters
Showing results (61-70 of 209) with videos related to
Page
of 21
Sort By:
The British Journal of Dermatology
|
October 15, 2025
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity
Mark G Lebwohl, Andrew Blauvelt, Jerry Bagel, et al.
Journal of Cutaneous Pathology
|
June 8, 2011
Amyloidosis cutis dyschromica associated with atypical Parkinsonism, spasticity and motor weakness in a Pakistani female
Neil F Fernandes, Stephen E Mercer, Rebecca Kleinerman, et al.
The Journal of Dermatological Treatment
|
June 16, 2021
Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis
Mark G Lebwohl, Linda Stein Gold, James Q Del Rosso, et al.
Journal of Drugs in Dermatology : JDD
|
August 21, 2018
What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab
Peter W Hashim, Tinley Chen, Mark G Lebwohl, et al.
Archives of Dermatology
|
June 23, 2010
Fatal influenza A(H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab
Maxwell C Kling, Amir A Larian, Irini Scordi-Bello, et al.
Journal of the American Academy of Dermatology
|
August 17, 2014
Reply to 'complementary data for long-term infliximab use in psoriasis'
Adam J Luber, Cindy L Tsui, Gillian M Heinecke, et al.
Seminars in Arthritis and Rheumatism
|
June 9, 2005
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel
Marc C Hochberg, Mark G Lebwohl, Scott E Plevy, et al.
Journal of the American Academy of Dermatology
|
March 17, 2015
Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors"
Sean D Doherty, Abby S Van Voorhees, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
January 7, 2014
Long-term durability and dose escalation patterns in infliximab therapy for psoriasis
Adam J Luber, Cindy L Tsui, Gillian M Heinecke, et al.
Dermatology and Therapy
|
September 12, 2024
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses
Mark G Lebwohl, April W Armstrong, Andrew F Alexis, et al.
Page
of 21
Search research articles
Search
Showing results (61-70 of 209) with videos related to
Sort By:
Page
of 21
The British Journal of Dermatology
|
October 15, 2025
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity
Mark G Lebwohl, Andrew Blauvelt, Jerry Bagel, et al.
Journal of Cutaneous Pathology
|
June 8, 2011
Amyloidosis cutis dyschromica associated with atypical Parkinsonism, spasticity and motor weakness in a Pakistani female
Neil F Fernandes, Stephen E Mercer, Rebecca Kleinerman, et al.
The Journal of Dermatological Treatment
|
June 16, 2021
Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis
Mark G Lebwohl, Linda Stein Gold, James Q Del Rosso, et al.
Journal of Drugs in Dermatology : JDD
|
August 21, 2018
What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab
Peter W Hashim, Tinley Chen, Mark G Lebwohl, et al.
Archives of Dermatology
|
June 23, 2010
Fatal influenza A(H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab
Maxwell C Kling, Amir A Larian, Irini Scordi-Bello, et al.
Journal of the American Academy of Dermatology
|
August 17, 2014
Reply to 'complementary data for long-term infliximab use in psoriasis'
Adam J Luber, Cindy L Tsui, Gillian M Heinecke, et al.
Seminars in Arthritis and Rheumatism
|
June 9, 2005
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel
Marc C Hochberg, Mark G Lebwohl, Scott E Plevy, et al.
Journal of the American Academy of Dermatology
|
March 17, 2015
Reply to: "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors"
Sean D Doherty, Abby S Van Voorhees, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
January 7, 2014
Long-term durability and dose escalation patterns in infliximab therapy for psoriasis
Adam J Luber, Cindy L Tsui, Gillian M Heinecke, et al.
Dermatology and Therapy
|
September 12, 2024
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses
Mark G Lebwohl, April W Armstrong, Andrew F Alexis, et al.
Page
of 21